Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in ω-3 polyunsaturated fatty acids

Cancer Research

Volumn 65, Issue 17, 2005, Pages 8022-8027

  Reddy, Bandaru S ^a,c   Patlolla, Jagan M ^b   Simi, Barbara ^a   Wang, S H ^a   Rao, Chinthalapally V ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; CARCINOGEN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FISH OIL; LIPID; OMEGA 3 FATTY ACID; POLYUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFICACY; ENZYME ACTIVITY; FAT INTAKE; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANIMALS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, OMEGA-3; MALE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, INBRED F344; SULFONAMIDES;

EID: 24744438276     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0212     Document Type: Article

References (42)

1. Stewart BW, Kleihuas P, editors. World cancer report: WHO. Lyon (France): IARC; 2003.
2. Jamal A, Murray T, Ward E, Samuels A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. World Cancer Research Fund and American Institute for Cancer Research, Panel on Food. Nutrition and the prevention of cancer. Washington (District of Columbia): American Institute for Cancer Research; 1997.
4. Caygill CP, Hill MJ. Fish, n-3 fatty acids and human colorectal and breast cancer mortality. Eur J Cancer Prev 1995;4:329-32.
5. Caygill CPJ, Charland SL, Lippin JA, Fat, fish, fish oil, and cancer. Br J Cancer 1996;74:159-64.
6. Anti M, Armelao F, Marra G. Effect of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas. Gastroenterology 1994;107:1709-18.
7. Chang W-CL, Chapkin RS, Lupton JR. Fish oil blocks azoxymethane-induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J Nutr 1998;128:491-7.
8. Minoura T, Takata T, Sakaguchi M, Takada H, Yamamura M, Yamamoto M. Effect of dietary eicosapentaenoic acid on azoxymethane-induced colon carcinogenesis. Cancer Res 1988;48:4790-4.
9. Rao CV, Hirose Y, Indranie C, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-33.
10. Reddy BS, Maruyama H. Effect of dietary fish oil on azoxymethane-induced colon carcinogenesis in male F 344 rats. Cancer Res 1986;46:3367-70.
11. Bull AW, Souiller BK, Wilson PS, Hayden MT, Nigro ND. Promotion of azoxymethane-induced intestinal cancer by high fat diets in rats. Cancer Res 1979;39:4956-9.
12. Yang K, Fan K, Newmark HL, et al. Cytokeratin, lectin, and acidic mucin modulation in differentiating colonic epithelial cells of mice after feeding Western-style diets. Cancer Res 1996;56:4644-8.
13. Reddy BS. Ω-3 fatty acids in colorectal cancer prevention. Int J Cancer 2004;112:1-7.
14. 6-methylguanine DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. Cancer Epidemiol Biomarkers Prev 2000;9:819-26.
15. Rao CV, Hirose Y, Cooma I, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-33.
16. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
17. Δ716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996;87:803-9.
18. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
19. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1 as well as Ptgs-2 reduces intestinal tumorigenesis in Min mice. Cancer Res 2000;60:4706-8.
20. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA, The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
21. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
22. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
23. Chiu CH, Mcentee MF, Whelan J. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997;57:4267-73.
24. Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res 1999;59:353-9.
25. Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998;124:225-31.
26. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-12.
27. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by COX-2 inhibitors. J Environ Pathol Toxicol Oncol 2002;21:155-64.
28. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of colon carcinogenesis. Cancer Res 2000;60:291-7.
29. Rao CV, Reddy BS. NSAIDs and Chemoprevention. Current Cancer Drug Targets 2004;4:29-42.
30. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
31. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duoderal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80;1618-9.
32. Reddy BS. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:239-47.
33. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
34. DuBois R, Radhika A, Reddy BS, Enting AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colon tumors. Gastroenterology 1996;110:1259-62.
35. Kargman S, O'Neill G, Vickers P, Evans J, Mancini J, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in colon cancer. Cancer Res 1995;55:2556-9.
36. Pozharisski KM. Tumors of the intestine: pathology of tumors in laboratory animals. IARC Sci Publ 1990;99:159-98.
37. Fan Y-Y, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRs in colonocytes. Carcinogenesis 2003;24:1541-8.
38. Narayanan BA, Narayanan NK, Reddy BS. Docasahexaenoic acid regulated genes and transcription factor inducing apoptosis in human colon cancer cells. Int J Oncol 2001;19:1255-62.
39. Narayanan BA, Narayanan NK, Desai D, Pittman B, Reddy BS. Effects of a combination of docosahexaenoic acid and 1.4-phenylenebis (methylene) selenocyanate on cyclooxygenase-2. inducible nitric oxide synthase and {β}-catenin pathways in colon cancer cells. Carcinogenesis 2004;25:2443-9.
40. Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nat Rev Cancer 2002;2:537-43.
41. Smith ML, Howcarft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer 2000;36:664-74.
42. Grosch S, Tegeder I, Niedererger E, Brautigam L, Gaisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;14:2742-4.